The success of immune checkpoint inhibitors, anti-CTLA-4 in treating melanoma and anti-PD-1/PD-L1 in multiple types of cancer, has emphasized the potential of immunotherapy as a promising treatment option for patients with hematologic malignancies. The gene discussed is CTLA4; the disease is hematologic disorder.